Your search for supplemental oxygen returned 15 results

The sBLA is supported by data from 4 randomized, controlled studies that evaluated tocilizumab for the treatment of COVID-19 in more than 5500 hospitalized patients.

Based on efficacy results from 2 phase 3 studies, Lilly has decided to discontinue development of baricitinib for lupus.

The update was based on data from the COV-BARRIER study.

Findings showed that the trial did not meet statistical significance on the primary endpoint.

The EUA was granted based on data from the phase 3 ACTT-2 trial, which was conducted by the NIAID.

Lenzilumab is an investigational anti-human granulocyte macrophage-colony stimulating factor monoclonal antibody.

Both randomized, placebo-controlled trials are expected to enroll approximately 1000 hospitalized patients.

The ACTT-2 study began on May 8 and included more than 1000 patients.

The placebo-controlled ACTT 3 trial will evaluate the efficacy and safety of remdesivir in combination with interferon beta-1a in more than 1000 hospitalized COVID-19 patients.

Acalabrutinib, a Bruton tyrosine kinase (BTK) inhibitor, appears to reduce respiratory distress as well as the hyperinflammatory immune response associated with coronavirus disease 2019.